Get the Stockscreener App
173.90
6.10%
10.00
Icon Plc stock is traded at $173.90, with a volume of 1.62M.
It is up +6.10% in the last 24 hours and up +0.24% over the past month.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
See More
Previous Close:
$163.90
Open:
$163.79
24h Volume:
1.62M
Relative Volume:
1.90
Market Cap:
$13.42B
Revenue:
$8.27B
Net Income/Loss:
$173.28M
P/E Ratio:
80.09
EPS:
2.1712
Net Cash Flow:
$785.90M
1W Performance:
+2.49%
1M Performance:
+0.24%
6M Performance:
+71.70%
1Y Performance:
+3.83%
1-Day Range:
$163.79
$175.00
1-Week Range:
$162.59
$175.00
52-Week Range:
$66.57
$203.91
Icon Plc Stock (ICLR) Company Profile
Compare ICLR vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
173.90 | 13.42B | 8.27B | 173.28M | 785.90M | 2.1712 |
TMO
Thermo Fisher Scientific Inc
|
678.39 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
223.77 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.79 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.84 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.02 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-23-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-17-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-12-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-26 | Downgrade | Truist | Buy → Hold |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
A Look at Icon PLC (ICLR) After 6.1% Gain -- GF Value $205.79 vs Price $173.90 - GuruFocus
ICON plc (ICLR) rises as investors appear to lean on backlog, guidance, and recent filings - quiverquant.com
Hybrid Clinical Research Associate Job at ICON | Apply Online Here - BioTecNika
ICON Public Limited Company’s (ICLR) Shrinking Moat Warranted an Early Departure - Currently.com
Icon PLC (ICLR) Stock Up 3.3% and Still Undervalued -- GF Score: 95/100 - GuruFocus
Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook - GlobeNewswire Inc.
ICON plc stock edges higher after analyst updates and steady Q2 figures - AD HOC NEWS
Icon PLC (ICLR) Stock Down 3.3% -- Now Undervalued? GF Score: 96/100 - GuruFocus
Citi Maintains Icon PLC(ICLR.US) With Hold Rating, Raises Target Price to $175 - Moomoo
ICLR Maintained by Citigroup -- Price Target Lowered to $175 - GuruFocus
Strategic Sale: DR JOHN CLIMAX Decides To Exercise Options Worth $204K At Icon - Benzinga
ICON PLC Director Eugene McCague Exercises Stock Options and Sells Shares on September 17, 2026 - kalkinemedia.com
S&P 500 Futures Rise in Premarket Trading; Xenon Pharmaceuticals, Icon PLC Lag - Barron's
Icon (ICLR) insider sells 5,005 shares after exercising options - Stock Titan
Director at ICON (ICLR) unloads stock right after exercising options - Stock Titan
Director at ICON (NASDAQ: ICLR) exercises options, then sells 5,005 shares - Stock Titan
Icon (ICLR) Stock Forecast and Price Target 2026 $ICLR - MarketBeat
ICON PLC (NASDAQ: ICLR) director plans 569,625 stock sale - Stock Titan
ICON (NASDAQ: ICLR) director plans to sell thousands of shares in 2026 - Stock Titan
ICON plc Q2 2026 Earnings: EPS Narrowly Misses Estimate as Stock Edges LowerProduct Revenue Analysis - careplusvn.com
ICON plc (NASDAQ: ICLR) director plans $876K sale after $138K trade - Stock Titan
ICON plcOrdinary Shares (Nasdaq:ICLR) Detailed Stock Data - The Chronicle-Journal
ICON plc (ICLR) Stock Analysis: Unpacking a 9.6% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ICON plc Stock Price: ICLR Stock Chart, Market Cap & News Today - CoinGecko
A Look at Icon PLC (ICLR) After 3.9% Gain -- GF Value $207.68 vs Price $165.69 - GuruFocus
ICON PLC (NASDAQ: ICLR) Releases Unaudited Interim Financial Statements in September 9 Filing - kalkinemedia.com
ICON taps Anthropic and Microsoft as it puts clinical-trial agents into production - R&D World
Is Icon PLC (ICLR) a Bargain After 4.1% Drop? GF Value Says Unde - GuruFocus
ICON plc (ICLR) Stock Report: Evaluating a 12.56% Potential Upside Amidst Healthcare Sector Expansion - DirectorsTalk Interviews
Long term debt to total equity ratio of ICON Plc – HAM:IJF - TradingView
Icon plc stock holds steady as Q2 2026 results support full-year guidance - ad-hoc-news.de
ICON Plc (ICLR) Stock Analysis: Exploring Growth Potential With A 9.14% Upside - DirectorsTalk Interviews
How ICON’s Mixed Q1 Earnings and Reaffirmed 2026 Outlook Could Impact ICON (ICLR) Investors - sahmcapital.com
Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
ICON plc (ICLR) Stock Analysis: Navigating Growth in Diagnostics & Research with a 7.74% Upside - DirectorsTalk Interviews
ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability - BioSpace
ICON plc (ICLR) posts top-1% ESG score and 73% emissions cut - Stock Titan
A Look at Icon PLC (ICLR) After 3.2% Gain -- GF Value $208.22 vs Price $172.49 - GuruFocus
ETFs Investing in ICON Plc Stocks - TradingView
ICON plc (NASDAQ: ICLR) swaps secured loans for $2.15B in new notes - Stock Titan
White & Case advises ICON on its US$2.15 billion notes offering and related secured debt refinancing - White & Case LLP
6-K: Icon PLC | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Icon PLC (ICLR) Shares Surge 3.9% -- What GF Score of 93 Tells I - GuruFocus
ICON plc (ICLR) Stock Analysis: Strong Buy Ratings and 13.74% Potential Upside Highlight Investment Appeal - DirectorsTalk Interviews
Icon CEO awarded $3.7m in shares as company emerges from turmoil - Irish Independent
Does ICON’s Shift to an Unsecured Capital Structure Reshape the Bull Case for ICLR? - Sahm
Icon Plc $ICLR Shares Bought by Handelsbanken Fonder AB - MarketBeat
Invesco Ltd. (ICLR) discloses 6.9% beneficial stake in ICON PLC - Stock Titan
Director Of Icon Makes $138K Sale - Benzinga
ICON plc (ICLR) Rises 0.96% to $167.17 on Steady CRO Sector DemandInstitutional Buy Signals - vinanet.vn
Trinity Street Asset Management LLP Raises Stock Position in Icon Plc $ICLR - MarketBeat
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):